Researchers at The University of Texas MD Anderson Cancer Center developed a novel chimeric mouse model to test the combination therapy
using immune checkpoint blockades with therapies targeting myeloid - derived suppressor cells (MDSCs).
Not exact matches
Researchers found the gene therapy approach had stronger results when
used in combination with either depletion of immunosuppressive cells from the tumor mass or with
immune checkpoint blockade.
In the next year, members of the Dream Team will continue to study the tumor microenvironment before and after
checkpoint blockade, to develop algorithms to identify and predict the best antigens on cancer cells that can be
used for cancer immunotherapies, to analyze tumor tissues and blood for biomarkers that will help in selecting patients who will benefit, and identifying the best approaches to increase the strength of
immune cells for adoptive cell therapy.
Allison is the person responsible for developing the
checkpoint blockade approach to cancer immunotherapy: antibodies are
used to target specific molecules on
immune cells, which empowers them to find and attack cancer cells.